---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-124995"
form_type: "8-K"
ticker: "CTSO"
cik: "0001175151"
company_name: "Cytosorbents Corp"
filed_at: "2023-12-11T23:59:59+00:00"
generated_at: "2026-06-07T14:43:00.680222+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CytoSorbents raises gross $10.3M in registered direct offering of common stock and warrants

## Summary
- Offers 7.73M shares plus warrants for 2.71M shares at $2.00 exercise price; combined price $1.33 per unit.
- Gross proceeds $10.29M; net ~$9.83M after expenses; closing expected Dec 12, 2023.
- Insiders (executives, directors, employees) purchase 327,070 shares and 114,465 warrants.
- Proceeds to fund DrugSorb-ATR marketing efforts, clinical studies, R&D, and working capital.
- Company states net proceeds plus existing cash fund operations into Q3 2024; seeks additional non-dilutive capital.

## SEC filing metadata
- accession: 0001104659-23-124995
- form_type: 8-K
- ticker: CTSO
- cik: 0001175151
- company_name: Cytosorbents Corp
- filed_at: 2023-12-11T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1175151/000110465923124995/0001104659-23-124995-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1175151/000110465923124995/tm2332399d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-124995
- JSON: https://secwatch.observer/filing/0001104659-23-124995.json
- Plain text: https://secwatch.observer/filing/0001104659-23-124995.txt

## Key facts
- Material Agreements
  Cytosorbents Corp entered into Purchase Agreement with certain institutional and accredited investors valued at aggregate gross purchase price of $10,285,009.70 (effective 2023-12-11).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain institutional and accredited investors
  - Value: aggregate gross purchase price of $10,285,009.70
  - Effective: 2023-12-11
  source text: On December 11, 2023, CytoSorbents Corporation (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional and accredited investors (collectively, the “Investors”) for the sale by the Company directly to the Investors of an aggregate of 7,733,090 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”) together with warrants (the “Warrants”) to purchase up to 2,706,561 shares of Common Stock
  evidence_url: https://www.sec.gov/Archives/edgar/data/1175151/000110465923124995/0001104659-23-124995-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.